Ottawa's push for lower drug costs may hurt patients, stunt innovation
鈥淭he federal government is potentially on a path that will limit access of Canadians to new life-saving drugs, while further discouraging the discovery of new medicines,鈥 said Steven Globerman, professor emeritus at Western Washington University, Fraser Institute senior fellow and study co-author.